164 related articles for article (PubMed ID: 37853018)
1. Untargeted lipidomics reveal association of elevated plasma C18 ceramide levels with reduced survival in metastatic castration-resistant prostate cancer patients.
Cattrini C; Manfredi M; Barboro P; Ghirimoldi M; Mennitto A; Martini V; Battioni A; Le Van M; Gobbato S; Branni C; Ayed RB; Pinato DJ; Catalano F; Zanardi E; Boccardo F; Gennari A
Sci Rep; 2023 Oct; 13(1):17791. PubMed ID: 37853018
[TBL] [Abstract][Full Text] [Related]
2. Aberrations in circulating ceramide levels are associated with poor clinical outcomes across localised and metastatic prostate cancer.
Lin HM; Huynh K; Kohli M; Tan W; Azad AA; Yeung N; Mahon KL; Mak B; Sutherland PD; Shepherd A; Mellett N; Docanto M; Giles C; Centenera MM; Butler LM; Meikle PJ; Horvath LG
Prostate Cancer Prostatic Dis; 2021 Sep; 24(3):860-870. PubMed ID: 33746214
[TBL] [Abstract][Full Text] [Related]
3. PCPro: a clinically accessible, circulating lipid biomarker signature for poor-prognosis metastatic prostate cancer.
Scheinberg T; Lin HM; Fitzpatrick M; Azad AA; Bonnitcha P; Davies A; Heller G; Huynh K; Mak B; Mahon K; Sullivan D; Meikle PJ; Horvath LG
Prostate Cancer Prostatic Dis; 2024 Mar; 27(1):136-143. PubMed ID: 37147359
[TBL] [Abstract][Full Text] [Related]
4. Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer.
Mak B; Lin HM; Kwan EM; Fettke H; Tran B; Davis ID; Mahon K; Stockler MR; Briscoe K; Marx G; Zhang A; Crumbaker M; Tan W; Huynh K; Meikle TG; Mellett NA; Hoy AJ; Du P; Yu J; Jia S; Joshua AM; Waugh DJ; Butler LM; Kohli M; Meikle PJ; Azad AA; Horvath LG
BMC Med; 2022 Mar; 20(1):112. PubMed ID: 35331214
[TBL] [Abstract][Full Text] [Related]
5. Maternal obesity leads to long-term altered levels of plasma ceramides in the offspring as revealed by a longitudinal lipidomic study in children.
León-Aguilar LF; Croyal M; Ferchaud-Roucher V; Huang F; Marchat LA; Barraza-Villarreal A; Romieu I; Ramakrishnan U; Krempf M; Ouguerram K; Mercado-Camargo R; Bolaños-Jiménez F
Int J Obes (Lond); 2019 Jun; 43(6):1231-1243. PubMed ID: 30568270
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Impact of Total Plasma Cell-free DNA Concentration in Androgen Receptor Pathway Inhibitor-treated Metastatic Castration-resistant Prostate Cancer.
Fettke H; Kwan EM; Bukczynska P; Ng N; Nguyen-Dumont T; Southey MC; Davis ID; Mant A; Parente P; Pezaro C; Hauser C; Azad AA
Eur Urol Focus; 2021 Nov; 7(6):1287-1291. PubMed ID: 32739405
[TBL] [Abstract][Full Text] [Related]
7. Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer.
Scher HI; Lu D; Schreiber NA; Louw J; Graf RP; Vargas HA; Johnson A; Jendrisak A; Bambury R; Danila D; McLaughlin B; Wahl J; Greene SB; Heller G; Marrinucci D; Fleisher M; Dittamore R
JAMA Oncol; 2016 Nov; 2(11):1441-1449. PubMed ID: 27262168
[TBL] [Abstract][Full Text] [Related]
8. Lipidomic studies revealing serological markers associated with the occurrence of retinopathy in type 2 diabetes.
He M; Hou G; Liu M; Peng Z; Guo H; Wang Y; Sui J; Liu H; Yin X; Zhang M; Chen Z; Rensen PCN; Lin L; Wang Y; Shi B
J Transl Med; 2024 May; 22(1):448. PubMed ID: 38741137
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors for clinical outcomes in patients with metastatic castration resistant prostate cancer treated with sequential novel androgen receptor-directed therapies.
Nadal R; Tsai HL; Sinibaldi VJ; Paller CJ; Antonarakis ES; Denmeade SR; Carducci MA; Eisenberger MA
Prostate; 2016 Apr; 76(5):512-20. PubMed ID: 26689606
[TBL] [Abstract][Full Text] [Related]
10. A distinct plasma lipid signature associated with poor prognosis in castration-resistant prostate cancer.
Lin HM; Mahon KL; Weir JM; Mundra PA; Spielman C; Briscoe K; Gurney H; Mallesara G; Marx G; Stockler MR; PRIMe Consortium ; Parton RG; Hoy AJ; Daly RJ; Meikle PJ; Horvath LG
Int J Cancer; 2017 Nov; 141(10):2112-2120. PubMed ID: 28741687
[TBL] [Abstract][Full Text] [Related]
11. Circulating Ceramides Predict Cardiovascular Outcomes in the Population-Based FINRISK 2002 Cohort.
Havulinna AS; Sysi-Aho M; Hilvo M; Kauhanen D; Hurme R; Ekroos K; Salomaa V; Laaksonen R
Arterioscler Thromb Vasc Biol; 2016 Dec; 36(12):2424-2430. PubMed ID: 27765765
[TBL] [Abstract][Full Text] [Related]
12. Association between specific plasma ceramides and high-sensitivity C-reactive protein levels in postmenopausal women with type 2 diabetes.
Mantovani A; Altomari A; Lunardi G; Bonapace S; Lippi G; Bonnet F; Targher G
Diabetes Metab; 2020 Sep; 46(4):326-330. PubMed ID: 31185304
[TBL] [Abstract][Full Text] [Related]
13. Association between plasma ceramides and inducible myocardial ischemia in patients with established or suspected coronary artery disease undergoing myocardial perfusion scintigraphy.
Mantovani A; Bonapace S; Lunardi G; Salgarello M; Dugo C; Canali G; Byrne CD; Gori S; Barbieri E; Targher G
Metabolism; 2018 Aug; 85():305-312. PubMed ID: 29777715
[TBL] [Abstract][Full Text] [Related]
14. Ceramide ratios are affected by cigarette smoke but not heat-not-burn or e-vapor aerosols across four independent mouse studies.
Lavrynenko O; Titz B; Dijon S; Santos DD; Nury C; Schneider T; Guedj E; Szostak J; Kondylis A; Phillips B; Ekroos K; Martin F; Peitsch MC; Hoeng J; Ivanov NV
Life Sci; 2020 Dec; 263():118753. PubMed ID: 33189821
[TBL] [Abstract][Full Text] [Related]
15. Multi-Omic Integration of Blood-Based Tumor-Associated Genomic and Lipidomic Profiles Using Machine Learning Models in Metastatic Prostate Cancer.
Fang S; Zhe S; Lin HM; Azad AA; Fettke H; Kwan EM; Horvath L; Mak B; Zheng T; Du P; Jia S; Kirby RM; Kohli M
JCO Clin Cancer Inform; 2023 Jul; 7():e2300057. PubMed ID: 37490642
[TBL] [Abstract][Full Text] [Related]
16. Independent prognostic impact of plasma NCOA2 alterations in metastatic castration-resistant prostate cancer.
Fettke H; Kwan EM; Bukczynska P; Steen JA; Docanto M; Ng N; Parente P; Mant A; Foroughi S; Pezaro C; Hauser C; Nguyen-Dumont T; Southey MC; Azad AA
Prostate; 2021 Sep; 81(13):992-1001. PubMed ID: 34254334
[TBL] [Abstract][Full Text] [Related]
17. Survival of Patients with Metastatic Prostate Cancer After Disease Progression on an Androgen Receptor Axis-Targeted Therapy Given in the Metastatic Castration-Sensitive Versus Metastatic Castration-Resistant Prostate Cancer Setting.
Sayegh N; Tripathi N; Nussenzveig RH; Thomas VM; Tandar C; Goel D; Nordblad B; Sahu KK; Li H; L Maughan B; Agarwal N; Swami U
Eur Urol Focus; 2023 Jan; 9(1):106-109. PubMed ID: 35835693
[TBL] [Abstract][Full Text] [Related]
18. Relationship between Circulating Lipids and Cytokines in Metastatic Castration-Resistant Prostate Cancer.
Lin HM; Yeung N; Hastings JF; Croucher DR; Huynh K; Meikle TG; Mellett NA; Kwan EM; Davis ID; Tran B; Mahon KL; Zhang A; Stockler MR; Briscoe K; Marx G; Bastick P; Crumbaker ML; Joshua AM; Azad AA; Meikle PJ; Horvath LG
Cancers (Basel); 2021 Oct; 13(19):. PubMed ID: 34638448
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Utility of a Whole-blood Androgen Receptor-based Gene Signature in Metastatic Castration-resistant Prostate Cancer.
Kwan EM; Fettke H; Docanto MM; To SQ; Bukczynska P; Mant A; Pook D; Ng N; Graham LK; Mangiola S; Segelov E; Mahon K; Davis ID; Parente P; Pezaro C; Todenhöfer T; Horvath LG; Azad AA
Eur Urol Focus; 2021 Jan; 7(1):63-70. PubMed ID: 31103601
[TBL] [Abstract][Full Text] [Related]
20. Association between Higher Circulating Leucine-Rich α-2 Glycoprotein 1 Concentrations and Specific Plasma Ceramides in Postmenopausal Women with Type 2 Diabetes.
Mantovani A; Csermely A; Sani E; Beatrice G; Petracca G; Lunardi G; Bonapace S; Lippi G; Targher G
Biomolecules; 2022 Jul; 12(7):. PubMed ID: 35883498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
